Cargando…
非小细胞肺癌EGFR和ALK基因双突变研究进展
Molecular target therapy is one of the most popular field of non-small cell lung cancer (NSCLC) treatmnet. Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearragement are the most important two oncogenic drivers in NSCLC, early studies suggested that EGFR mutat...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136996/ https://www.ncbi.nlm.nih.gov/pubmed/30201068 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.09.07 |